Article Text

Download PDFPDF
Does radiotherapy have a role in the management of thyroid orbitopathy? View 1
  1. Kimberley P Cockerham1,
  2. John S Kennerdell1
  1. 1Allegheny General Hospital, 420 East North Avenue, Pittsburgh, PA 15212-9986, USA
  1. Correspondence to: Dr Alan A McNab

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The use of radiotherapy in managing patients with thyroid orbitopathy is controversial. There are widely divergent results from studies of its effectiveness in treating patients and its place in management of thyroid orbitopathy remains uncertain. In this clinical controversy two groups involved in studies exploring the effectiveness of radiotherapy in thyroid orbitopathy discuss their views of the role of radiotherapy in managing patients with thyroid orbitopathy.

Thyroid orbitopathy (thyroid associated orbitopathy or Graves' ophthalmopathy) is a common cause of proptosis, eyelid retraction, orbital congestion, and motility disturbances in adults. Each patient experiences a unique combination of symptoms and signs for an unpredictable duration and with varying severity. Although orbital manifestations typically improve within 2–5 years, these years feel like a century to the extremely uncomfortable and discontented patients. In addition, visual loss due to optic nerve compression does occur. Radiotherapy has a key role in the management of moderate to severe inflammatory symptoms and is effective treatment for optic nerve compromise.

Our understanding of the link between systemic thyroid disease and orbitopathy has expanded greatly over the past 20 years, although the precise pathogenesis remains uncertain. An unknown mechanism allows thyroid antigen to stimulate the immune system and produce antibodies to the thyroid stimulating hormone (TSH) receptor and other antigens that alter the release of thyroid hormones. Shared orbit thyroid antigens result in the production of activated T lymphocytes that invade the orbital connective tissue.1,2 Orbital fibroblasts proliferate, resulting in increased synthesis and release of glycosaminoglycans. Locally produced cytokines amplify the inflammatory response. This combined cell mediated and humoral response results in inflammatory cell migration and production of oedema in the orbit. The result is thickening of extraocular muscle and an increase in orbital fat volume. External beam radiation can intervene in this process by arresting the fibroblast …

View Full Text

Footnotes

  • Series editors: Susan Lightman & Peter McCluskey

Linked Articles

  • BJO at a glance
    Creig Hoyt